|
Pronunciation |
|
(pen
i SIL in vee poe TASS ee
um) |
|
|
U.S. Brand
Names |
|
Beepen-VK®; Betapen®-VK;
Pen.Vee® K; Robicillin® VK; Veetids® |
|
|
Generic
Available |
|
Yes |
|
|
Canadian Brand
Names |
|
Apo®-Pen VK; Nadopen-V®;
Novo-Pen-VK®; Nu-Pen-VK; PVF® K |
|
|
Synonyms |
|
Pen VK; Phenoxymethyl Penicillin |
|
|
Pharmacological Index |
|
Antibiotic, Penicillin |
|
|
Use |
|
Dental: Antibiotic of first choice in treating common orofacial infections
caused by aerobic gram-positive cocci and anaerobes. These orofacial infections
include cellulitis, periapical abscess, periodontal abscess, acute suppurative
pulpitis, oronasal fistula, pericoronitis, osteitis, osteomyelitis, postsurgical
and post-traumatic infection. It is no longer recommended for dental procedure
prophylaxis.
Medical: Treatment of infections caused by susceptible organisms involving
the respiratory tract, otitis media, sinusitis, skin, and urinary tract;
prophylaxis in rheumatic fever |
|
|
Pregnancy Risk
Factor |
|
B |
|
|
Contraindications |
|
Known hypersensitivity to penicillin or any component |
|
|
Warnings/Precautions |
|
Use with caution in patients with severe renal impairment (modify dosage),
history of seizures, or hypersensitivity to cephalosporins |
|
|
Adverse
Reactions |
|
>10%: Gastrointestinal: Mild diarrhea, vomiting, nausea, oral candidiasis
<1%: Convulsions, fever, hemolytic anemia, positive Coombs' reaction,
acute interstitial nephritis, hypersensitivity reactions, anaphylaxis
|
|
|
Overdosage/Toxicology |
|
Symptoms of penicillin overdose include neuromuscular hypersensitivity
(agitation, hallucinations, asterixis, encephalopathy, confusion, and seizures)
and electrolyte imbalance with potassium or sodium salts, especially in renal
failure
Hemodialysis may be helpful to aid in the removal of the drug from the blood,
otherwise most treatment is supportive or symptom directed |
|
|
Drug
Interactions |
|
Decreased effect: Tetracyclines may decrease penicillin effectiveness;
decreased oral contraceptive effect is possible
Increased effect:
Probenecid may increase penicillin levels
Aminoglycosides may result in synergistic efficacy; heparin and parenteral
penicillins may result in increased bleeding |
|
|
Stability |
|
Refrigerate suspension after reconstitution; discard after 14
days |
|
|
Mechanism of
Action |
|
Inhibits bacterial cell wall synthesis by binding to one or more of the
penicillin binding proteins (PBPs); which in turn inhibits the final
transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus
inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing
activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while
cell wall assembly is arrested. |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Oral: 60% to 73% from GI tract
Distribution: Appears in breast milk
Plasma protein binding: 80%
Half-life: 0.5 hours; prolonged in patients with renal impairment
Time to peak serum concentration: Oral: Within 0.5-1 hour
Elimination: Penicillin V and its metabolites are excreted in urine mainly by
tubular secretion |
|
|
Usual Dosage |
|
Oral:
Children <12 years: 25-50 mg/kg/day in divided doses every 6-8 hours;
maximum dose: 3 g/day
Children greater than or equal to 12 years and Adults: 125-500 mg every 6-8
hours
Prophylaxis of pneumococcal infections:
Children <5 years: 125 mg twice daily
Children greater than or equal to 5 years and Adults: 250 mg twice daily
Prophylaxis of recurrent rheumatic fever:
Children <5 years: 125 mg twice daily
Children greater than or equal to 5 years and Adults: 250 mg twice daily
Dosing interval in renal impairment: Clcr <10
mL/minute: Administer 250 mg every 6 hours |
|
|
Dietary
Considerations |
|
Food: Decreases drug absorption rate; decreases drug serum concentration.
Take on an empty stomach 1 hour before or 2 hours after
meals. |
|
|
Monitoring
Parameters |
|
Periodic renal and hematologic function tests during prolonged therapy;
monitor for signs of anaphylaxis during first dose |
|
|
Test
Interactions |
|
False-positive or negative urinary glucose determination using
Clinitest®; positive Coombs' [direct]; false-positive
urinary and/or serum proteins |
|
|
Mental Health: Effects
on Mental Status |
|
Penicillins reported to cause apprehension, illusions, hallucinations,
depersonalization, agitation, insomnia, and encephalopathy |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
Prolonged use of penicillins may lead to development of oral
candidiasis |
|
|
Patient
Information |
|
Take at regular intervals around-the-clock, preferably on an empty stomach (1
hour before or 2 hours after meals) with 8 oz of water. Take entire
prescription; do not skip doses or discontinue without consulting prescriber.
Small frequent meals, frequent mouth care, sucking lozenges, or chewing gum may
reduce nausea or dry mouth. Important to maintain good oral and vaginal hygiene
to reduce incidence of opportunistic infection. If diabetic, drug may cause
false tests with Clinitest® urine glucose monitoring; use
of glucose oxidase methods (Clinistix®) or serum glucose
monitoring is preferable. This drug may interfere with oral contraceptives; an
alternate form of birth control should be used. Report persistent diarrhea,
fever, chills, unhealed sores, bloody urine or stool, muscle pain, mouth sores,
and difficulty breathing. |
|
|
Nursing
Implications |
|
Administer around-the-clock rather than 4 times/day, 3 times/day, etc, (ie,
12-6-12-6, not 9-1-5-9) to promote less variation in peak and trough serum
levels; dosage modification required in patients with renal
insufficiency |
|
|
Dosage Forms |
|
250 mg = 400,000 units
Tablet: 125 mg, 250 mg, 500 mg |
|
|
References |
|
Dajani AS, Bisno AL, Chung KJ, et al,
"Prevention of Rheumatic Fever. A Statement for Health Professionals by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, The American Heart Association,"
Pediatr Infect Dis J, 1989, 8(5):263-6.
Wynn RL and Bergman SA,
"Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,"
Gen Dent, 1994, 42(5):398-402, 498-502.
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|